The company also confirmed that ABS-1230 has been accepted into the U.S. Food and Drug Administration’s Rare Disease Evidence Principles (RDEP) process
The test is designed to help clinicians either rule in or rule out amyloid pathology in patients showing signs of cognitive decline
Researchers reported that patients treated with the wearable system were discharged around five days earlier than those receiving standard hospital-based care
High-resolution analytical platforms from Agilent Technologies will be made available through C-CAMP’s shared infrastructure model under expanded collaboration
The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments
Pan-India multidisciplinary program aims to improve coordinated care for patients with chronic kidney disease and heart failure
Shashwat Goenka takes over as Vice President of industry body
Lormalzi is the first and only once-monthly amyloid plaque-targeting therapy with clinical evidence
The two companies will establish a joint Center of Excellence (CoE) in Bengaluru
Subscribe To Our Newsletter & Stay Updated
